Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;44(10):2139-2151.
doi: 10.1007/s40618-020-01491-3. Epub 2021 Feb 17.

Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer

A Matrone #  1 , A Prete #  1 , A Nervo  2 , A Ragni  2 , L Agate  1 , E Molinaro  1 , C Giani  1 , L Valerio  1 , E Minaldi  1 , A Piovesan  2 , R Elisei  3
Affiliations

Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer

A Matrone et al. J Endocrinol Invest. 2021 Oct.

Erratum in

Abstract

Purpose: Patients with advanced progressive metastatic medullary thyroid cancer (MTC), show poor prognosis and few available systemic therapeutic options. After the loss of clinical benefit with other tyrosine kinase inhibitors (TKI), we evaluated the use of lenvatinib as salvage therapy.

Methods: Ten patients who experienced the loss of clinical benefit after treatment with at least one previous TKI, were treated with lenvatinib. We assessed patient's response immediately before, at the first (first-EV) and last (last-EV) evaluation, after the beginning of treatment.

Results: At first-EV, one patient died, while all the remaining 9 showed a stable disease (SD) in the target lesions. At last-EV, SD was still observed in seven patients, while partial response (PR) and progressive disease (PD), in one patient each. Conversely, analyzing all target and non-target lesions, at first-EV, we observed PR in one patient and SD in eight patients. At last-EV, PR was shown in two patients and SD was shown in seven. Bone metastases showed stable disease control at both first-EV and last-EV in only approximately 60% of cases. Tumor markers (CTN and CEA) decreased at first-EV, while they increased at last-EV. Seven patients experienced at least one dose reduction during treatment with lenvatinib.

Conclusions: In this real-life clinical experience, lenvatinib showed interesting results as salvage therapy in patients with advanced progressive metastatic MTC patients. Its usefulness could be effective in patients without any other available treatment, because previously used or unsuitable, especially with negative RET status with no access to the new highly selective targeted therapies.

Keywords: Calcitonin; Carcinoembrionic antigen; Lenvatinib; Medullary thyroid cancer; Tyrosine kinase inhibitors.

PubMed Disclaimer

References

    1. Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid: Off J Am Thyroid Assoc 25(6):567–610. https://doi.org/10.1089/thy.2014.0335 - DOI
    1. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, Schlumberger M, Bigorgne JC, Dumontier P, Leclerc L, Corcuff B, Guilhem I (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs a calcitonine. Clin Endocrinol 48(3):265–273 - DOI
    1. Kuo EJ, Sho S, Li N, Zanocco KA, Yeh MW, Livhits MJ (2018) Risk factors associated with reoperation and disease-specific mortality in patients with medullary thyroid carcinoma. JAMA Surg 153(1):52–59. https://doi.org/10.1001/jamasurg.2017.3555 - DOI - PubMed
    1. Ceolin L, Duval M, Benini AF, Ferreira CV, Maia AL (2019) Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives. Endocr Relat Cancer 26(9):R499–R518. https://doi.org/10.1530/ERC-18-0574 - DOI - PubMed
    1. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI (2009) Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol: Off J Am Soc Clin Oncol 27(23):3794–3801. https://doi.org/10.1200/JCO.2008.18.7815 - DOI

MeSH terms

Supplementary concepts

LinkOut - more resources